Healius Limited (ASX:HLS)

Market Cap	428.42M -58.0%
Revenue (ttm)	1.37B +6.0%
Net Income	-168.80M
EPS	-0.23
Shares Out	726.13M
PE Ratio	n/a
Forward PE	47.20
Dividend	0.41 (71.21%)
Ex-Dividend Date	May 9, 2025

Volume	2,193,322
Average Volume	4,347,003
Open	0.6000
Previous Close	0.5900
Day's Range	0.5800 - 0.6000
52-Week Range	0.5670 - 1.6350
Beta	0.26
RSI	26.33
Earnings Date	Feb 18, 2026

About Healius

Healius Limited provides medical laboratory and pathology services in Australia. The company provides services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetnostics Pathology, QML Pathology, TML Pathology, Abbott Pathology, IQ Pathology, Kossard, Gastrolab, and Agilex Biolabs brands. It operates medical laboratories and patient collection centers. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1994
• Employees: 8,224
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: HLS

Financial Performance

In fiscal year 2025, Healius's revenue was 1.34 billion, an increase of 5.69% compared to the previous year's 1.27 billion. Losses were -151.20 million, -76.59% less than in 2024.